Prolight Diagnostics AB today announces that it has signed a commercialisation agreement for its proprietary point-of-care (POC) platform PLD Micro Flex with its technology and development partner, The Technology Partnership plc (TTP), in Cambridge, UK. Under the agreement, TTP will pursue further development and ongoing external initiatives and discussions with the aim of securing an industrial partner for PLD Micro Flex. Prolight Diagnostics will benefit under the commercialisation agreement as future revenues are generated.
“We strongly believe in the PLD Micro Flex technology but need to prioritise our resources. We chose TTP as our commercialisation partner as it has detailed knowledge of PLD Micro Flex and an extensive commercial network in the diagnostics market. TTP has the technical know-how and business development expertise necessary to pursue ongoing external initiatives and discussions with the aim of securing the right industrial partner for PLD Micro Flex. Through this agreement, Prolight Diagnostics will be renumerated as future revenues are generated,” said Ulf Bladin, CEO of Prolight Diagnostics.
“Having worked with Prolight in developing the PLD Micro Flex platform, we are excited to be part of the next stages of its commercialisation. We look forward to fruitful discussions as we seek a commercial partner for the platform and the technology” said Giles Sanders, Head of Diagnostics at TTP.
PLD Micro Flex, which combines the technologies of TTP (Flex Membrane technology) and Prolight Diagnostics (microformat ELISA technology), has the potential to achieve equivalent test performance as hospital laboratories in a format suitable for widely distributed diagnostic testing.
TTP is a leading technology development business based near Cambridge, UK, with some 240 researchers and designers working with cutting edge companies all over the world, bringing advanced technologies to market.